Literature DB >> 22322081

High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries).

Peter Ong1, Anastasios Athanasiadis, Gabor Borgulya, Heiko Mahrholdt, Juan Carlos Kaski, Udo Sechtem.   

Abstract

OBJECTIVES: This study aimed at determining the prevalence of epicardial and microvascular coronary spasm in patients with anginal symptoms, despite angiographically normal coronary arteries.
BACKGROUND: Despite a typical clinical presentation with exercise-related anginal symptoms (chest pain or dyspnea) with or without occasional attacks of resting chest pain suggestive of coronary artery disease, 40% of patients undergoing diagnostic angiography have normal or "near" normal coronary arteriograms. Many of these patients are given a diagnosis of noncardiac chest pain, and some are considered to have microvascular angina. However, we speculate that abnormal coronary vasomotion (reduced vasodilatation with exercise = reduced coronary flow reserve and/or vasospasm at rest) might also represent a plausible explanation for the symptoms of the patient.
METHODS: This was a prospective study in 304 consecutive patients (50% men, mean age 66 ± 10 years) with exertional anginal symptoms undergoing diagnostic angiography. A total of 139 patients (46%) had ≥50% coronary artery disease in at least 1 coronary artery, 21 patients (7%) had luminal narrowings ranging from >20% to 49%, and 144 patients (47%) had normal coronary arteries or only minimal irregularities (<20% diameter reduction).
RESULTS: One hundred twenty-four patients of the latter (86%) underwent intracoronary acetylcholine (ACH) testing, which elicited coronary spasm in 77 patients (62%), 35 patients (45%) with epicardial spasm (≥75% diameter reduction with reproduction of the symptoms of the patient) and 42 patients (55%) with microvascular spasm (reproduction of symptoms, ischemic electrocardiographic changes, and no epicardial spasm).
CONCLUSIONS: Nearly 50% of patients undergoing diagnostic angiography for assessment of stable angina had angiographically normal or near normal coronary arteriograms. The ACH test triggered epicardial or microvascular coronary spasm in nearly two-thirds of these patients. Our results suggest that abnormal coronary vasomotion plays a pathogenic role in this setting and that the ACH test might be useful to identify patients with cardiac symptoms, despite normal coronaries. (Abnormal Coronary Vasomotion in Patients With Suspected CAD But Normal Coronary Arteries; NCT00921856).
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322081     DOI: 10.1016/j.jacc.2011.11.015

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  97 in total

Review 1.  Emergence of Nonobstructive Coronary Artery Disease: A Woman's Problem and Need for Change in Definition on Angiography.

Authors:  Carl J Pepine; Keith C Ferdinand; Leslee J Shaw; Kelly Ann Light-McGroary; Rashmee U Shah; Martha Gulati; Claire Duvernoy; Mary Norine Walsh; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2015-10-27       Impact factor: 24.094

Review 2.  Diagnosis of coronary microvascular dysfunction - Present status.

Authors:  S R Mittal
Journal:  Indian Heart J       Date:  2015-11-06

3.  How to differentiate the etiology of LV dysfunction as to whether it is "ischemic cardiomyopathy" or "dilated non-ischemic cardiomyopathy"? Invasive coronary and myocardial assessment is the approach of first choice.

Authors:  Sung Gyun Ahn; Habib Samady
Journal:  J Nucl Cardiol       Date:  2015-07-08       Impact factor: 5.952

4.  Coronary vasomotor abnormalities in patients with stable angina after successful stent implantation but without in-stent restenosis.

Authors:  Peter Ong; Anastasios Athanasiadis; Andrea Perne; Heiko Mahrholdt; Tim Schäufele; Stephan Hill; Udo Sechtem
Journal:  Clin Res Cardiol       Date:  2013-09-01       Impact factor: 5.460

5.  Case report: assessment and management of myocardial infarction and non-obstructive coronary arteries (MINOCA): the role of microvascular coronary vasospasm.

Authors:  ReddySailaja Marpuri; Sandy Joung; Adit Gadh; Shivani Dhawan; Ahmed Al-Badri; Christine Pacheco; Janet Wei; C Noel Bairey Merz
Journal:  Cardiovasc Diagn Ther       Date:  2019-08

Review 6.  2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations.

Authors:  Lawrence R Krakoff; Robert L Gillespie; Keith C Ferdinand; Icilma V Fergus; Ola Akinboboye; Kim A Williams; Mary Norine Walsh; C Noel Bairey Merz; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2014-07-29       Impact factor: 24.094

Review 7.  Overview of the Acetylcholine Spasm Provocation Test.

Authors:  Shozo Sueda; Hiroaki Kohno; Takaaki Ochi; Tadao Uraoka
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

Review 8.  Endothelial dysfunction: its clinical value and methods of assessment.

Authors:  Teresa Strisciuglio; Stefania De Luca; Ernesto Capuano; Rossella Luciano; Tullio Niglio; Bruno Trimarco; Gennaro Galasso
Journal:  Curr Atheroscler Rep       Date:  2014-06       Impact factor: 5.113

9.  Myocardial ischemia without obstructive CAD: there is more than meets the eye!

Authors:  Danilo Neglia; Riccardo Liga
Journal:  J Nucl Cardiol       Date:  2017-06-05       Impact factor: 5.952

10.  Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).

Authors:  John W Petersen; Puja K Mehta; Tanya S Kenkre; R David Anderson; B Delia Johnson; Chrisandra Shufelt; Bruce Samuels; Saibal Kar; Babak Azarbal; Eileen Handberg; Kamlesh Kothawade; Carl J Pepine; C Noel Bairey Merz
Journal:  Int J Cardiol       Date:  2014-01-04       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.